These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8006099)

  • 1. Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatography.
    Roth JS; Kelley JA; Chun HG; Ward FT
    J Chromatogr; 1994 Feb; 652(2):149-59. PubMed ID: 8006099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
    Conley BA; Sewack GF; Egorin MJ; Subramanyam B; Page JG; Grieshaber CK
    Cancer Chemother Pharmacol; 1991; 28(1):33-8. PubMed ID: 2040031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans.
    Callery PS; Egorin MJ; Geelhaar LA; Nayar MS
    Cancer Res; 1986 Oct; 46(10):4900-3. PubMed ID: 3756851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
    Subramanyam B; Callery PS; Egorin MJ; Snyder SW; Conley BA
    Drug Metab Dispos; 1989; 17(4):398-401. PubMed ID: 2571479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
    Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA
    Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide.
    Egorin MJ; Zuhowski EG; Nayar MS; Callery PS
    J Chromatogr; 1987 Mar; 415(1):148-55. PubMed ID: 3584350
    [No Abstract]   [Full Text] [Related]  

  • 7. Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
    Conley BA; Callery PS; Egorin MJ; Subramanyam B; Geelhaar LA; Pan SS
    Life Sci; 1988; 43(9):793-800. PubMed ID: 3137409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.
    Snyder SW; Egorin MJ; Geelhaar LA; Hamburger AW; Callery PS
    Cancer Res; 1988 Jul; 48(13):3613-6. PubMed ID: 3163938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells.
    Egorin MJ; Snyder SW; Cohen AS; Zuhowski EG; Subramanyam B; Callery PS
    Cancer Res; 1988 Apr; 48(7):1712-6. PubMed ID: 3162401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
    Ward FT; Kelley JA; Roth JS; Lombardo FA; Weiss RB; Leyland-Jones B; Chun HG
    Cancer Res; 1991 Apr; 51(7):1803-10. PubMed ID: 2004365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of hexamethylene bisacetamide in biological fluids and tissues by RP-HPLC].
    Ling F; Fan L; Zhao L; Chen L
    Se Pu; 1997 Sep; 15(5):458-9. PubMed ID: 15739509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of hexamethylene bisacetamide, an antineoplastic compound, in mouse and human plasma by LC-MS/MS.
    Smith KM; Ketchart W; Zhou X; Montano MM; Xu Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2206-12. PubMed ID: 21723208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane.
    Snyder SW; Egorin MJ; Zuhowski EG; Schimpff EC; Callery PS
    Cancer Commun; 1990; 2(7):231-6. PubMed ID: 2378784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gas chromatographic determination of atenolol in biological samples.
    Scales B; Copsey PB
    J Pharm Pharmacol; 1975 Jun; 27(6):430-3. PubMed ID: 237092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrophobic chromatography of the HL-60 cellular fraction co-binding with hexamethylene bisacetamide.
    Xie D; Li S; Ren L
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):359-63. PubMed ID: 9061477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.
    Rowinsky EK; Ettinger DS; Grochow LB; Brundrett RB; Cates AE; Donehower RC
    J Clin Oncol; 1986 Dec; 4(12):1835-44. PubMed ID: 3783206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
    Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
    Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to optimal dosing of hexamethylene bisacetamide.
    Conley BA; Egorin MJ; Sinibaldi V; Sewack G; Kloc C; Roberts L; Zuhowski EG; Forrest A; Van Echo DA
    Cancer Chemother Pharmacol; 1992; 31(1):37-45. PubMed ID: 1333894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of hexamethylene bisacetamide by capillary gas chromatography.
    Walsh TD; Fanucchi MP
    J Chromatogr; 1987 Mar; 414(2):510-3. PubMed ID: 3571421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.